BD's Q1 Earnings Call: Our Top 5 Analyst Questions
Is now the time to buy BDX? Find out in our full research report (it's free).
Revenue: $5.27 billion vs analyst estimates of $5.35 billion (4.5% year-on-year growth, 1.5% miss)
Adjusted EPS: $3.35 vs analyst estimates of $3.28 (2.1% beat)
Adjusted EBITDA: $1.52 billion vs analyst estimates of $1.54 billion (28.9% margin, 1.1% miss)
Adjusted EPS guidance for the full year is $14.20 at the midpoint, missing analyst estimates by 1.2%
Operating Margin: 10.4%, down from 14.5% in the same quarter last year
Constant Currency Revenue rose 6% year on year (4.7% in the same quarter last year)
Market Capitalization: $48.98 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Larry Biegelsen (Wells Fargo) asked for clarity on the magnitude and mitigation of tariff expenses, with CFO Chris DelOrefice explaining that the $0.25 per share impact is net of mitigation efforts and would need to be partially annualized for next year.
Robbie Marcus (JPMorgan) pressed on specific drivers behind the downward revision in organic growth, with DelOrefice breaking down the headwinds as primarily stemming from China, research spending cuts, and slow diagnostic recovery.
Matt Taylor (Jefferies) explored the company's levers for managing tariffs, prompting CEO Tom Polen to detail inventory repositioning, supplier shifts, and the use of alternate global manufacturing sites to reduce exposure.
Travis Steed (Bank of America) questioned the credibility of the accelerated growth outlook for the second half, with management conceding that macro volatility has made guidance more difficult but expressing confidence in the pipeline of launches and operational execution.
Patrick Wood (Morgan Stanley) asked about sustaining internal efficiency programs, to which Polen and President Mike Feld highlighted that the BD Excellence initiatives are still expanding and viewed as energizing for employees, freeing up time for value-added work.
In the coming quarters, the StockStory team will be monitoring (1) the pace of recovery in diagnostics and research funding environments, (2) successful ramp-up and market uptake of new product launches such as FACSDiscover A8 and CentroVena One, and (3) the effectiveness of tariff mitigation strategies as the external landscape evolves. Execution on the planned business separation and further margin improvements through BD Excellence will also be key signposts.
BD currently trades at $170.90, down from $206.90 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it's free).
Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNBC
an hour ago
- CNBC
Tom Lee: This is the most hated V-shaped rally
Fundstrat's Tom Lee, NewEdge Wealth's Cameron Dawson and Wells Fargo's Chris Harvey join 'Closing Bell' to discuss the latest news affecting markets.
Yahoo
9 hours ago
- Yahoo
Earnings Preview: What to Expect From Becton, Dickinson and Company's Report
Becton, Dickinson and Company (BDX) develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products. Valued at $52.3 billion by market cap, the company offers solutions that help advance medical research and genomics, enhance the diagnosis of infectious diseases and cancer, improve medication management, and promote infection prevention. The global medical technology giant is expected to announce its fiscal third-quarter earnings for 2025 before the market opens on Thursday, Aug. 7. Ahead of the event, analysts expect BDX to report a profit of $3.42 per share on a diluted basis, down 2.3% from $3.50 per share in the year-ago quarter. The company has consistently surpassed Wall Street's EPS estimates in its last four quarterly reports. More News from Barchart UnitedHealth Stock Spirals Lower Again. Don't Buy the Dip. This Self-Driving Car Stock Is Surging on a Major Nvidia Boost Auto Revenue Keeps Plunging at Tesla. Should You Buy the TSLA Stock Dip or Run Far Away? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. For the full year, analysts expect BDX to report EPS of $14.17, up 7.8% from $13.14 in fiscal 2024. Its EPS is expected to rise 3.4% year over year to $14.65 in fiscal 2026. BDX stock has significantly underperformed the S&P 500 Index's ($SPX) 17.3% gains over the past 52 weeks, with shares down 22.6% during this period. Similarly, it underperformed the Health Care Select Sector SPDR Fund's (XLV) 9.4% dip over the same time frame. BDX's underperformance is attributed to a software recall in its Alaris infusion pump systems. Software issues in the Alaris Systems Manager and Care Coordination Engine Infusion Adapter can cause delayed responses and potentially incorrect therapy administration, posing risks to patient safety. The recall affects critical components that integrate the pump with hospital electronic medical record systems. On May 1, BDX shares closed down more than 18% after reporting its Q2 results. Its adjusted EPS of $3.35 exceeded Wall Street's expectations of $3.28. The company's revenue was $5.3 billion, falling short of Wall Street forecasts of $5.4 billion. BDX expects full-year adjusted EPS in the range of $14.06 to $14.34, and expects revenue in the range of $21.8 billion to $21.9 billion. Analysts' consensus opinion on BDX stock is reasonably bullish, with an overall 'Moderate Buy' rating. Out of 17 analysts covering the stock, seven advise a 'Strong Buy' rating, one suggests a 'Moderate Buy,' and nine give a 'Hold.' BDX's average analyst price target is $213.71, indicating a potential upside of 16.4% from the current levels. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
16 hours ago
- Yahoo
Wells Fargo Cuts Elevance (ELV) Price Target on Margin Uncertainty
Elevance Health, Inc. (NYSE:ELV) ranks among the . Wells Fargo kept its Overweight rating on Elevance Health, Inc. (NYSE:ELV) on July 15, but lowered its price target on the health insurer from $478 to $400. Wells Fargo applied a lower multiple of 10.5x to its 2026 earnings per share projection of $38.05, which is less than the previous multiple of 11.5x. designer491/ Wells Fargo stated that the primary driver of the reduced value multiple was uncertainty regarding margins in the Medicaid, Medicare Advantage (MA), and Health Insurance Exchange (HIX) segments for 2025. The firm also pointed out that there was 'relatively low visibility to improvement in 2026,' especially in the Medicaid and Health Insurance Exchange segments. However, it insisted that Elevance's valuation 'remains compelling once dust settles on estimates.' Elevance Health, Inc. (NYSE:ELV), previously Anthem, Inc., is a leading health-benefits provider in the United States. The company offers medical, pharmaceutical, dental, long-term care, disability, and behavioral health insurance under numerous brands, including Anthem Blue Cross, Blue Shield, Wellpoint, and Carelon. While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.